$BNTC
Benitec Biopharma Inc. Stock $bntc

$bntc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000119312522237075 Filed on September 02, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$0.00	$0.00	$73.00K
YoY Change		-100.0%	23.73%
Cost Of Revenue		$9.000K	$9.000K
YoY Change			-92.68%
Gross Profit		-$9.000K	$64.00K
YoY Change			-200.0%
Gross Profit Margin			87.67%
Selling, General & Admin	$1.920M	$1.553M	$6.646M
YoY Change	-5.97%	1.11%	2.06%
% of Gross Profit			10384.38%
Research & Development	$2.660M	$3.176M	$11.27M
YoY Change	-4.32%	36.9%	60.57%
% of Gross Profit			17612.5%
Depreciation & Amortization	$42.00K		$167.0K
YoY Change	-19.23%		-27.71%
% of Gross Profit			260.94%
Operating Expenses	$4.580M	$4.729M	$17.93M
YoY Change	-5.02%	22.61%	32.48%
Operating Profit	-$4.580M	-$4.738M	-$17.85M
YoY Change	-5.02%		31.32%
Interest Expense	-$9.000K	-$279.0K	-$32.00K
YoY Change	-95.96%	88.51%	-90.09%
% of Operating Profit
Other Income/Expense, Net	-$513.0K	-$50.00K	-$354.0K
YoY Change			-1056.76%
Pretax Income	-$5.093M	-$5.067M	-$17.37M
YoY Change	0.95%	26.58%	25.12%
Income Tax
% Of Pretax Income
Net Earnings	-$5.100M	-$5.067M	-$18.21M
YoY Change	1.09%	26.58%	31.16%
Net Earnings / Revenue			-24942.47%
Basic Earnings Per Share	-$0.47		-$2.23
Diluted Earnings Per Share	-$0.47	-$620.1K	-$2.23
COMMON SHARES
Basic Shares Outstanding	8.172M		8.172M
Diluted Shares Outstanding	10.86M		8.172M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.53M	$4.062M	$4.062M
YoY Change	5.13%	-79.45%	-79.45%
Cash & Equivalents	$16.50M	$4.100M	$4.062M
Short-Term Investments
Other Short-Term Assets	$531.0K	$741.0K	$755.0K
YoY Change	-17.29%	-8.97%	-7.25%
Inventory
Prepaid Expenses	$643.0K	$871.0K
Receivables	$3.000K	$3.000K	$3.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.08M	$4.820M	$4.820M
YoY Change	4.33%	-76.61%	-76.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$179.0K	$222.0K	$993.0K
YoY Change	-85.91%	-61.53%	72.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$119.0K	$135.0K	$160.0K
YoY Change	-38.66%	-30.41%	-17.53%
Total Long-Term Assets	$1.034M	$1.153M	$1.153M
YoY Change	-29.37%	49.55%	49.55%
TOTAL ASSETS
Total Short-Term Assets	$17.08M	$4.820M	$4.820M
Total Long-Term Assets	$1.034M	$1.153M	$1.153M
Total Assets	$18.12M	$5.973M	$5.973M
YoY Change	1.56%	-72.06%	-72.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$608.0K	$422.0K	$422.0K
YoY Change	88.24%	54.01%	54.01%
Accrued Expenses	$2.275M	$2.039M	$2.039M
YoY Change	90.86%	121.39%	121.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.011M	$2.532M	$2.532M
YoY Change	88.07%	84.95%	84.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$491.0K	$559.0K	$559.0K
YoY Change	-35.39%
Total Long-Term Liabilities	$491.0K	$559.0K	$559.0K
YoY Change	-35.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.011M	$2.532M	$2.532M
Total Long-Term Liabilities	$491.0K	$559.0K	$559.0K
Total Liabilities	$3.502M	$3.091M	$3.091M
YoY Change	48.33%	125.79%	125.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.4M	-$148.3M
YoY Change		13.99%
Common Stock	$168.8M	$152.5M
YoY Change		0.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.61M	$2.882M	$2.882M
YoY Change
Total Liabilities & Shareholders Equity	$18.12M	$5.973M	$5.973M
YoY Change	1.56%	-72.06%	-72.06%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$5.100M	-$5.067M	-$18.21M
YoY Change	1.09%	26.58%	31.16%
Depreciation, Depletion And Amortization	$42.00K		$167.0K
YoY Change	-19.23%		-27.71%
Cash From Operating Activities	-$4.000M	-$4.855M	-$15.90M
YoY Change	-6.5%	-5.76%	23.91%
INVESTING ACTIVITIES
Capital Expenditures		-$13.00K	$13.00K
YoY Change		-109.35%	-105.88%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00	-$13.00K	-$13.00K
YoY Change		-109.35%	-94.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.02M	0.000	0.000
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-4.000M	-4.855M	-15.90M
Cash From Investing Activities	0.000	-13.00K	-13.00K
Cash From Financing Activities	16.02M	0.000	0.000
Net Change In Cash	12.47M	-4.868M	-15.71M
YoY Change	-391.51%	-163.56%	-265.89%
FREE CASH FLOW
Cash From Operating Activities	-$4.000M	-$4.855M	-$15.90M
Capital Expenditures		-$13.00K	$13.00K
Free Cash Flow		-$4.842M	-$15.91M
YoY Change		-8.49%	26.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4620206
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001808898
CY2019Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39267
CY2022	dei	Entity Registrant Name EntityRegistrantName	Benitec Biopharma Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3940 Trust Way
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
CY2022	dei	City Area Code CityAreaCode	510
CY2022	dei	Local Phone Number LocalPhoneNumber	780-0819
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2022	dei	Trading Symbol TradingSymbol	BNTC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	21383111
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8171690
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2022	dei	Auditor Location AuditorLocation	Campbell, California
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4062000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3000
CY2021Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	25000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	741000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	799000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	4820000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	20608000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000
CY2022Q2	us-gaap	Deposit Assets DepositAssets	25000
CY2021Q2	us-gaap	Deposit Assets DepositAssets	9000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	771000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	202000
CY2022Q2	us-gaap	Assets Assets	5973000
CY2021Q2	us-gaap	Assets Assets	21379000
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1880000
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	880000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	400000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	276000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	213000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2532000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1369000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	559000
CY2022Q2	us-gaap	Liabilities Liabilities	3091000
CY2021Q2	us-gaap	Liabilities Liabilities	1369000
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8171690
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8171690
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8171690
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8171690
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152453000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	151583000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148327000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130119000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1245000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1455000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2882000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	20010000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5973000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21379000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	73000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	59000
CY2022	bntc	Royalties And License Fees RoyaltiesAndLicenseFees	9000
CY2021	bntc	Royalties And License Fees RoyaltiesAndLicenseFees	123000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11272000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7020000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6646000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6512000
CY2022	us-gaap	Operating Expenses OperatingExpenses	17927000
CY2021	us-gaap	Operating Expenses OperatingExpenses	13655000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17854000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13596000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-232000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-333000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-32000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-6000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-79000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-11000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-354000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-286000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	210000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	498000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	210000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	498000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17998000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13384000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8171690
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8171690
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4295416
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4295416
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	10238000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3228000
CY2021	bntc	Issuance And Exercise Of Prefunded Warrants Net Of Transaction Costs IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts	22519000
CY2021	bntc	Warrants Exercised Value During The Period WarrantsExercisedValueDuringThePeriod	3000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	634000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	498000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	20010000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	870000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	210000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2882000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	167000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	231000
CY2022	bntc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	225000
CY2021	bntc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	193000
CY2022	bntc	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	-10000
CY2021	bntc	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	16000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	870000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	634000
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1000
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-28000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4000
CY2022	bntc	Increasedecrease In Accounts And Other Payables IncreasedecreaseInAccountsAndOtherPayables	1090000
CY2021	bntc	Increasedecrease In Accounts And Other Payables IncreasedecreaseInAccountsAndOtherPayables	55000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	80000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	121000
CY2022	bntc	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-196000
CY2021	bntc	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-192000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15899000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12832000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-221000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25750000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3228000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22522000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	204000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15708000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9968000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9816000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4076000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4062000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4076000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	794000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2019-11-22
CY2019Q4	bntc	Common Stock Shares Redomiciliation Description CommonStockSharesRedomiciliationDescription	one Benitec Biopharma Inc. share for every 300 BBL shares
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8171690
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001808898
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </div></div></div>
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39267
CY2022	dei	Entity Registrant Name EntityRegistrantName	Benitec Biopharma Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3940 Trust Way
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
CY2022	dei	City Area Code CityAreaCode	510
CY2022	dei	Local Phone Number LocalPhoneNumber	780-0819
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2022	dei	Trading Symbol TradingSymbol	BNTC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	21383111
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2022	dei	Auditor Location AuditorLocation	Campbell, California
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4062000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3000
CY2021Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	25000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	741000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	799000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	4820000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	20608000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000
CY2022Q2	us-gaap	Deposit Assets DepositAssets	25000
CY2021Q2	us-gaap	Deposit Assets DepositAssets	9000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6891
CY2021Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.7506
CY2022	bntc	Average Foreign Exchange Rate For The Period AverageForeignExchangeRateForThePeriod	0.7254
CY2021	bntc	Average Foreign Exchange Rate For The Period AverageForeignExchangeRateForThePeriod	0.747
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	202000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	845159
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	809159
CY2022Q2	us-gaap	Assets Assets	5973000
CY2021Q2	us-gaap	Assets Assets	21379000
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1880000
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19784000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1455000
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prior Period Reclassification </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the prior period have been reclassified to conform with current period presentation. </div></div></div>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18200000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13900000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12800000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4100000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	771000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	73000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	59000
CY2022Q2	us-gaap	Due From Banks DueFromBanks	4062000
CY2021Q2	us-gaap	Due From Banks DueFromBanks	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4076000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	871000
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	967000
CY2022Q2	bntc	Market Value Of Listed Shares MarketValueOfListedShares	5000
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	880000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	400000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	276000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	213000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2532000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1369000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	559000
CY2022Q2	us-gaap	Liabilities Liabilities	3091000
CY2021Q2	us-gaap	Liabilities Liabilities	1369000
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8171690
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8171690
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8171690
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8171690
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152453000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	151583000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148327000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130119000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1245000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2882000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	20010000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5973000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21379000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	73000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	59000
CY2022	bntc	Royalties And License Fees RoyaltiesAndLicenseFees	9000
CY2021	bntc	Royalties And License Fees RoyaltiesAndLicenseFees	123000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11272000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7020000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6646000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6512000
CY2022	us-gaap	Operating Expenses OperatingExpenses	17927000
CY2021	us-gaap	Operating Expenses OperatingExpenses	13655000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17854000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13596000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-232000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-333000
CY2021Q2	bntc	Market Value Of Listed Shares MarketValueOfListedShares	17000
CY2022Q2	us-gaap	Other Assets OtherAssets	876000
CY2021Q2	us-gaap	Other Assets OtherAssets	984000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	741000
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	799000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1404000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1393000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1182000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1018000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000
CY2022	us-gaap	Depreciation Depreciation	167000
CY2021	us-gaap	Depreciation Depreciation	231000
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	422000
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	274000
CY2022Q2	bntc	Accrued Licence Fees Current AccruedLicenceFeesCurrent	120000
CY2021Q2	bntc	Accrued Licence Fees Current AccruedLicenceFeesCurrent	140000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	131000
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	36000
CY2022Q2	bntc	Accrued Opmd Project Costs Current AccruedOpmdProjectCostsCurrent	-1089000
CY2021Q2	bntc	Accrued Opmd Project Costs Current AccruedOpmdProjectCostsCurrent	-279000
CY2022Q2	bntc	Accrued Consultant Fees Current AccruedConsultantFeesCurrent	47000
CY2021Q2	bntc	Accrued Consultant Fees Current AccruedConsultantFeesCurrent	36000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	71000
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	115000
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1880000
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	880000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	193000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	202000
CY2022	bntc	Operating Lease Right Of Use Asset Remasurement During The Period OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod	794000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	225000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	771000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	192000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	213000
CY2022	bntc	Remeasurement Of Lease Liabilities During The Period RemeasurementOfLeaseLiabilitiesDuringThePeriod	794000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	196000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	811000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	559000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y11M15D
CY2022Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0467
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-32000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-6000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-79000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-11000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-354000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-286000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	210000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	498000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	210000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	498000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17998000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13384000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8171690
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8171690
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4295416
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4295416
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	10238000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3228000
CY2021	bntc	Issuance And Exercise Of Prefunded Warrants Net Of Transaction Costs IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts	22519000
CY2021	bntc	Warrants Exercised Value During The Period WarrantsExercisedValueDuringThePeriod	3000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	634000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	498000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	20010000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	870000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	210000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2882000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	167000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	231000
CY2022	bntc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	225000
CY2021	bntc	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	193000
CY2022	bntc	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	-10000
CY2021	bntc	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	16000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	285000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	295000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	291000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	871000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	811000
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	145424
CY2020Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	29.48
CY2021	bntc	Class Of Warrants Or Rights Grants In Period ClassOfWarrantsOrRightsGrantsInPeriod	559162
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Granted During The Period WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod	3.09
CY2021	bntc	Class Of Warrants Or Rights Excercised During The Period ClassOfWarrantsOrRightsExcercisedDuringThePeriod	559162
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod	3.1
CY2021	bntc	Class Of Warrants Or Rights Cashless Exercise Of Warrants ClassOfWarrantsOrRightsCashlessExerciseOfWarrants	38329
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period Cash Less Exercise Of Warrants WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants	82.5
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	107095
CY2021Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	10.5
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	107095
CY2021Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	10.5
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7911000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-839000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5971000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.6
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.68
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.221
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.274
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0044
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0055
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	870000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	634000
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	522000
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1266000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17369000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17348000
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15902000
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	348000
CY2021Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	230000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	870000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	634000
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1000
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-28000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-62000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4000
CY2022	bntc	Increasedecrease In Accounts And Other Payables IncreasedecreaseInAccountsAndOtherPayables	1090000
CY2021	bntc	Increasedecrease In Accounts And Other Payables IncreasedecreaseInAccountsAndOtherPayables	55000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	80000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	121000
CY2022	bntc	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-196000
CY2021	bntc	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-192000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15899000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12832000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-221000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25750000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3228000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22522000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	204000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15708000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9968000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9816000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4076000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4062000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4076000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19784000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	794000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2019-11-22
CY2019Q4	bntc	Common Stock Shares Redomiciliation Description CommonStockSharesRedomiciliationDescription	one Benitec Biopharma Inc. share for every 300 BBL shares
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q2	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0
CY2021	bntc	Class Of Warrants Or Rights Excercised During The Period ClassOfWarrantsOrRightsExcercisedDuringThePeriod	559162
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod	3.1
CY2021	bntc	Class Of Warrants Or Rights Cashless Exercise Of Warrants ClassOfWarrantsOrRightsCashlessExerciseOfWarrants	38329
CY2022Q2	bntc	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	170000
CY2021Q2	bntc	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	45000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	205000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	88000
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	250000
CY2021Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	212000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18321000
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16477000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17965000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16223000
CY2022Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	162000
CY2021Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	42000
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	43000
CY2021Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	76000
CY2022Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	151000
CY2021Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	136000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	356000
CY2021Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	254000
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1742
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	bntc	Effective Income Tax Reconciliation Percentage Permanent Differences EffectiveIncomeTaxReconciliationPercentagePermanentDifferences	-0.0022
CY2021	bntc	Effective Income Tax Reconciliation Percentage Permanent Differences EffectiveIncomeTaxReconciliationPercentagePermanentDifferences	-0.089
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0036
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2055
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.139
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0212
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related right-of-use asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </div></div></div>
CY2021Q2	bntc	Accrued Opmd Project Costs Current AccruedOpmdProjectCostsCurrent	-279000
CY2022Q2	bntc	Accrued Consultant Fees Current AccruedConsultantFeesCurrent	47000
CY2021Q2	bntc	Accrued Consultant Fees Current AccruedConsultantFeesCurrent	36000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	71000
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6891
CY2021Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.7506
CY2022	bntc	Average Foreign Exchange Rate For The Period AverageForeignExchangeRateForThePeriod	0.7254
CY2021	bntc	Average Foreign Exchange Rate For The Period AverageForeignExchangeRateForThePeriod	0.747
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div>
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8171690
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8171690
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4295416
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4295416
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	115000
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1880000
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	880000
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period Cash Less Exercise Of Warrants WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants	82.5
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	845159
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	809159
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prior Period Reclassification </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the prior period have been reclassified to conform with current period presentation. </div></div></div>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18200000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13900000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15900000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12800000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4100000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	73000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	59000
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	145424
CY2020Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	29.48
CY2021	bntc	Class Of Warrants Or Rights Grants In Period ClassOfWarrantsOrRightsGrantsInPeriod	559162
CY2021	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Granted During The Period WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod	3.09
CY2022Q2	us-gaap	Due From Banks DueFromBanks	4062000
CY2021Q2	us-gaap	Due From Banks DueFromBanks	19769000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	14000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4076000
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19784000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	871000
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	967000
CY2022Q2	bntc	Market Value Of Listed Shares MarketValueOfListedShares	5000
CY2021Q2	bntc	Market Value Of Listed Shares MarketValueOfListedShares	17000
CY2022Q2	us-gaap	Other Assets OtherAssets	876000
CY2021Q2	us-gaap	Other Assets OtherAssets	984000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	741000
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	799000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1404000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1393000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1182000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1018000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000
CY2022	us-gaap	Depreciation Depreciation	167000
CY2021	us-gaap	Depreciation Depreciation	231000
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	422000
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	274000
CY2022Q2	bntc	Accrued Licence Fees Current AccruedLicenceFeesCurrent	120000
CY2021Q2	bntc	Accrued Licence Fees Current AccruedLicenceFeesCurrent	140000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	131000
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	36000
CY2022Q2	bntc	Accrued Opmd Project Costs Current AccruedOpmdProjectCostsCurrent	-1089000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	193000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	202000
CY2022	bntc	Operating Lease Right Of Use Asset Remasurement During The Period OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod	794000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	225000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	771000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	192000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	213000
CY2022	bntc	Remeasurement Of Lease Liabilities During The Period RemeasurementOfLeaseLiabilitiesDuringThePeriod	794000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	196000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	811000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	559000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y11M15D
CY2022Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0467
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	285000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	295000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	291000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	871000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	811000
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	107095
CY2021Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	10.5
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	107095
CY2021Q2	bntc	Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding	10.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.6
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.68
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.221
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.274
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0044
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0055
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	870000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	634000
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	522000
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1266000
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1742
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17369000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7911000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-839000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5971000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17348000
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15902000
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	348000
CY2021Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	230000
CY2022Q2	bntc	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	170000
CY2021Q2	bntc	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	45000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	205000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	88000
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	250000
CY2021Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	212000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18321000
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16477000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17965000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16223000
CY2022Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	162000
CY2021Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	42000
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	43000
CY2021Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	76000
CY2022Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	151000
CY2021Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	136000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	356000
CY2021Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	254000
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	bntc	Effective Income Tax Reconciliation Percentage Permanent Differences EffectiveIncomeTaxReconciliationPercentagePermanentDifferences	-0.0022
CY2021	bntc	Effective Income Tax Reconciliation Percentage Permanent Differences EffectiveIncomeTaxReconciliationPercentagePermanentDifferences	-0.089
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0036
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2055
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.139
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0212
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q2	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18208000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13882000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8171690
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8171690
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4295416
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4295416
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23

Files In Submission

Name	View Source	Status
0001193125-22-237075-index-headers.html	Edgar Link	pending
0001193125-22-237075-index.html	Edgar Link	pending
0001193125-22-237075.txt	Edgar Link	pending
0001193125-22-237075-xbrl.zip	Edgar Link	pending
bntc-20220630.xsd	Edgar Link	pending
bntc-20220630_cal.xml	Edgar Link	unprocessable
bntc-20220630_def.xml	Edgar Link	unprocessable
d360350d10k.htm	Edgar Link	pending
d360350dex211.htm	Edgar Link	pending
d360350dex231.htm	Edgar Link	pending
d360350dex311.htm	Edgar Link	pending
d360350dex312.htm	Edgar Link	pending
d360350dex321.htm	Edgar Link	pending
d360350dex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g360350g10.jpg	Edgar Link	pending
g360350g13.jpg	Edgar Link	pending
g360350g14.jpg	Edgar Link	pending
g360350g15.jpg	Edgar Link	pending
g360350g16a.jpg	Edgar Link	pending
g360350g16b.jpg	Edgar Link	pending
g360350g17a.jpg	Edgar Link	pending
g360350g17b.jpg	Edgar Link	pending
g360350g19.jpg	Edgar Link	pending
g360350g20.jpg	Edgar Link	pending
g360350g21.jpg	Edgar Link	pending
g360350g22.jpg	Edgar Link	pending
g360350g23.jpg	Edgar Link	pending
g360350g24.jpg	Edgar Link	pending
g360350g27.jpg	Edgar Link	pending
g360350g47s12.jpg	Edgar Link	pending
g360350g8.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
bntc-20220630_pre.xml	Edgar Link	unprocessable
d360350d10k_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bntc-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BNTC
Benitec Biopharma Inc. Stock $bntc

2022 Q3 Form 10-K Financial Statement

#000119312522237075 Filed on September 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNTC Benitec Biopharma Inc. Stock $bntc

2022 Q3 Form 10-K Financial Statement

#000119312522237075 Filed on September 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNTC
Benitec Biopharma Inc. Stock $bntc